Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04216433 |
Other study ID # |
2012.00.591.A |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 2012 |
Est. completion date |
July 1, 2021 |
Study information
Verified date |
December 2021 |
Source |
Methodist Health System |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
In the spirit of improving patient safety and quality of healthcare in our region, the
Dallas-Fort Worth Hospital Council Education and Research Foundation (Foundation) and Baylor
Research Institute sought and obtained federal funding support (AHRQ grant) to develop an
Abdominal Aortic Aneurism (AAA) surgery registry in North Texas. Participating centers will
directly benefit from this project and will have access to a de-identified version of the
registry data through their collaboration. These data may be used for quality improvement
initiatives and/or to conduct your own research. In summary, this effort represents a
substantial investment (with no costs to facilities) in improving outcomes for patients with
AAA.
Description:
Currently, little is known about who receives which type of surgery. What data are available
are largely from single-centre studies, with study populations of a few hundred to a thousand
patients, comparing outcomes for open and endovascular repair and collecting patient
characteristic data largely for risk adjustment. Data on endovascular vs open AAA repair from
the population-based registry will provide important information regarding the current use of
these two treatment strategies, as well as allowing comparison of long-term outcomes for each
according to different patient characteristics.
The proposed registry has the potential to provide means for internal quality assessment for
the participating institutions. The de-identified registry will be made available to
researchers at their request. This registry, focusing on AAA in the Dallas-Fort Worth
metroplex, will provide data with the potential to improve treatments for more than 800,000
patients in the US.